Knight and TherapeuticsMD announce Health Canada approval of Imvexxy

Knight Therapeutics

25 August 2020 - Knight Therapeutics and TherapeuticsMD announced today the approval of Imvexxy by Health Canada. In Canada, Imvexxy is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy. 

Imvexxy is an applicator-free, estradiol soft gel vaginal capsule indicated for postmenopausal women who experience pain before, during or after sex. Imvexxy (estradiol vaginal inserts) is marketed by TherapeuticsMD in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada